Antiretroviral Therapy
Initiating Antiretroviral Therapy in Treatment-Naive Patients
- ART is recommended for all HIV infected individuals regardless of CD4 count to decrease morbidity & mortality associated w/ HIV infectionda
- Urgent initiation of ART is recommended in the following individuals:
- Pregnant women
- HIV w/ coinfections (HBV, HCV, active tuberculosis)
- AIDS-defining illness, including HIV associated dementia (HAD) & AIDS-associated malignancies
- HIV-associated nephropathy (HIVAN)
- Low CD4 counts (eg <200 cells/mm3)
- Acute opportunistic infections (eg cryptosporidiosis, microsporidoisis & progressive multifocal leukoencephalopathy), as well as in patients w/ early/acute infections
- HIV HBV w/ evidence of chronic liver disease
- ART is also recommended for serodiscordant couples
- When initiating ART, it is important to educate patients about its benefits & considerations in order to optimize compliance to therapy
ART in Special Populations
- All pregnant & breastfeeding women w/ acute or recent HIV infection should start ART regimen as soon as possible to prevent mother-to-child transmission
- Principles of active TB treatment in HIV-infected patients are the same as those for HIV-uninfected patients
- All HIV patients coinfected w/ active TB should be immediately started on TB treatment
- CD4 counts <50 cells/mm3: Start ART w/in 2 weeks of TB treatment
- CD4 counts ≥50 cells/mm3 w/ severe clinical disease: Start w/in 2-4 weeks of TB treatment
- CD4 counts ≥50 cells/mm3 w/o severe clinical disease: ART may be started w/in 8-12 weeks of TB treatment
- In patients w/ HBV coinfection, ART drugs active against HBV should be continued even in the setting of HIV virologic failure
- The drug active against HBV should be continued & combined w/ other suitable ART agents to achieve HIV suppression
- Concurrent treatment of HIV and hepatitis C (HCV) infection may be complicated by overlapping drug toxicities & high pill burden
- Decision to start HCV treatment should consider medical need for such treatment based on HCV stage
- ART is recommended in patients >50 years of age regardless of CD4 count because immunologic response to ART may be reduced in older HIV-infected patients & the risk of non-AIDS complications may increase
- ART is recommended for all individuals w/ HIV-1 infection & should be offered to those w/ early HIV-1 infection, although definitive data to confirm whether this approach will result in long-term virologic, immunologic, or clinical benefits are lacking
- If treatment is initiated in a patient w/ early HIV-1 infection, the goal is to suppress plasma HIV-1 RNA to undetectable levels
- In patients w/ early HIV-1 infection in whom therapy is initiated, testing for plasma HIV-1 RNA levels, CD4 T lymphocyte counts, & toxicity monitoring should be performed as described for patients w/ chronic HIV-1 infection
- Genotypic drug resistance testing should be performed before initiation of ART to guide the selection of the regimen
- In patients w/o transmitted drug resistant virus, therapy should be initiated w/ one of the combination regimens for patients w/ chronic HIV-1 infection
- ART can be initiated before drug resistance test results are available
- Patients starting ART should be willing & able to commit to treatment & should understand the possible benefits & risks of therapy & the importance of adherence
Regimen Selection
- Selection of treatment regimen should be individualized based on virologic efficacy, toxicity, potential drug-drug interaction, dosing frequency, pill burden, resistance testing results, comorbidities, patient characteristics (eg pregnancy potential, adherence potential) & needs
- First-line agents should include 2 NRTIs plus an NNRTI
- Second-line agents should include 2 NRTIs plus a Ritonavir-boosted PI (eg ATV/r & LPV/r)
- Third-line agents should include new drugs w/ minimal potential for cross-resistance w/ prior regimens (eg integrase inhibitors, 2nd-generation NNRTIs and PIs)
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based Regimens 1,2
- Advantage: Have demonstrated virologic potency & durability
- Disadvantage: Prevalence of NNRTI-resistant viral strains in ART-naive patients & the low genetic barrier of these agents for the development of resistance
- All NNRTIs except for Etravirine (ETV) require only a single gene mutation to confer resistance; cross resistance among these NNRTIs are common
- A singe tablet formulation consisting of EFV, Tenofovir (TDF) & Emtricitabine (FTC) allows one-tablet, once-daily dosing & is currently the preferred NNRTI-based regimen
- Regimen consisting of RPV/TDF/FTC is only an alternative due to the limited data on durability to response & lower virologic response to RPV
Delavirdine (DLV)
- Requires 3-times daily dosing & has the least supporting data in clinical trials
- Appears to have the least antiviral activity & as such is not recommended as part of an initial ART regimen
- Adverse Reactions
- Dermatologic effect (rash); CNS effects (headache, depressive symptoms, fever, anxiety); GI effects (N/V, diarrhea, abdominal pain); Endocrine & metabolic effects (elevated transaminases, amylase & bilirubin levels); Hematologic effects (increased prothrombin time, decreased hemoglobin level)
- Special Instructions
- May be administered w/ or w/o food
- Rash occurs frequently & may require discontinuation of therapy; usually occurs w/in 1-3 wks & lasts <2 wks. Most patients may resume therapy following a treatment interruption
- Concurrent use of Astemizole, Terfenadine, ergot derivatives, Cisapride, Pimozide, Alprazolam, Midazolam, Triazolam is contraindicated
Efavirenz (EFV)
- Adverse Reactions
- Dermatologic effect (rash including Stevens-Johnson syndrome & erythema multiforme, pruritus); CNS effects (dizziness, headache, insomnia, somnolence, abnormal dreams, fatigue, impaired concentration, depression, anxiety, psychosis, amnesia, ataxia); GI effects (nausea, less frequently vomiting, diarrhea, hepatitis, abdominal pain); Other effects (gynecomastia, blurred vision)
- Special Instructions
- Discontinue use if severe skin rash or fever develops
- Contraindicated in severe hepatic impairment
- Use w/ caution in renal impairment & in mild to moderate liver disease; monitor liver enzymes & cholesterol level
- Use w/ caution in known or suspected hepatitis B infection, in those w/ history of mental illness, seizures
- Dosage Guidelines
- 600 mg PO 24 hrly on an empty stomach
Etravirine (ETV)
- Advantage: Has in-vitro activity against some viruses w/ mutations that confer resistance to DLV, EFV, & Nevirapine (NVP)
- Disadvantage: In RPV-treated patients, presence of RPV-resistant mutations at virologic failure is common & may confer cross-resistance to ETV
- Adverse Reactions
- Dermatologic effect (rash); GI effects (N/V, abdominal pain); Metabolic effects (elevated total cholesterol, hyperglycemia, increased ALT & creatinine levels); CV effect (hypertension); CNS effect (peripheral neuropathy)
- May cause fat redistribution & immune reconstitution syndrome
- Special Instructions
- Should be taken w/ food; swallow whole, do not crush
- Discontinue use if severe skin rash develops
- Unboosted protease inhibitors (ie w/o low-dose Ritonavir) should not be used w/ Etravirine
- Dosage Guidelines
- 200 mg PO 12 hrly after meals
Nevirapine (NVP)
- Advantage: May be used as an acceptable NNRTI option in women w/ baseline CD4 counts of <250 cells/mm3 or in men w/ pretreatment CD4 counts <400 cells/mm3
- Disadvantage: Serious hepatic events have been observed when started in ART-naive patients
- However, patients who experience increases in CD4 count to levels above the aforementioned thresholds can safely continue w/o an increased risk for hepatic events
- Monitoring of serum transaminases at baseline, 2 weeks after dose increase & then monthly for the first 18 weeks are recommended by some experts
- Adverse Reactions
- Dermatologic effect (rash); GI effects (N/V, abnormal liver function tests, diarrhea, abdominal pain); CNS effects (headache, fatigue)
- Special Instructions
- May be taken w/ or w/o food
- Re-introduce at a lower dose for the first 14 days if treatment is interrupted for >7 days
- Contraindicated in severe hepatic impairment
- Interrupt treatment if severe hepatotoxicity or life-threatening skin reactions develop
- Use w/ caution in renal or hepatic insufficiency; monitor liver function periodically
- Dosage Guidelines
- Initial dose: 200 mg PO 24 hrly x 14 days
- Maintenance dose: 200 mg PO 12 hrly
Rilpivrine (RPV)
- May be used in combination w/ NRTIs for ART-naive patients w/pre-treatment viral load <100,000 copies/mL
- Use of RPV w/ TDF/FTC should be limited to ART-naive patients w/ pre-treatment viral load copies of <100,000 & CD4 count >200 cell/mm3
- Advantage: A once daily dosing & is coformulated w/ TDF/TFC; Compared w/ EFV, drug discontinuations w/ RPV due to adverse effects (eg dizziness, abnormal dreams, hyperlipidemia & rash) were less frequent
- Frequency of depressive disorders & discontinuations secondary to depression are similar between RPV & EFV
- Disadvantage: Lower virologic response compared w/ EFV in patients w/ high baseline viral loads & requires acid to have an adequate absorption
- Adverse Reactions
- CNS effects (depression, dysphoria, mood changes, negative thoughts, suicidal ideation, headache, insomnia); Dermatologic effect (rash); Endocrine & metabolic effects (increased LDL, total cholesterol & triglyceride levels); Hepatic effects (elevated liver transaminases & bilirubin levels); Renal effect (elevated creatinine level)
- Special Instructions
- Administer w/ food
- Concurrent use of Carbamazepine, Dexamethasone (>1 dose), Oxcarbazepine, Phenobarbital, Phenytoin, PPIs, Rifabutin, Rifampin, Rifapentine, St. John’s wort is contraindicated
1 Combinations of NNRTIs & NRTIs are available. Specific prescribing information may be found in the latest MIMS.
2 Drug interactions listed above may not be comprehensive. Please see the latest MIMS for complete drug interaction & full prescribing information.
Top
Protease (PI)-based Regimens 1
- Have demonstrated durability & virologic potency in ART-naive patients
- Resistance mutations are seldom detected at virologic failure, unlike NNRTI- & Integrase Strand Transfer Inhibitor (INSTI)-based regimens
- PIs cause dyslipidemia including elevated triglycerides (TG) & high cholesterol along w/ a redistribution in body fat
- They also cause hyperglycemia
Amprenavir (APV)
- Adverse Reactions
- CNS effects (tremors, mood disorders, oral or perioral paresthesia); GI effects (N/V, diarrhea); Endocrine effects (dyslipidemia, redistribution of body fat, buffalo hump, facial atrophy, breast enlargement); Dermatologic effect (rash)
- Special Instructions
- May be taken w/ or w/o food, but do not take w/ a high-fat meal
- Contraindicated in sulfonamide allergy, renal or hepatic failure, concomitant Metronidazole or Disulfiram therapy
- Use w/ caution in diabetes mellitus (DM), when patient is on Sildenafil & vit E supplement
- Use oral solution only when capsule & other PIs are not therapeutic options
- Potentially fatal interactions w/ drugs w/ narrow therapeutic index (eg Cisapride, Terfenadine, Pimozide, Guanidine, Rifampicin)
- Dosage Guidelines
- Capsules:
- Combined w/ Ritonavir: 600 mg PO 12 hrly
- Combined w/ other antiretrovirals: 1200 mg PO 12 hrly
- Oral soln:
- 17 mg/kg PO 8 hrly
- Max dose: 2.8 g/day
Darunavir (DRV)
- Adverse Reactions
- GI effects (diarrhea, abdominal pain, N/V, constipation); CNS effect (headache); Other effects (nasopharyngitis, lipodystrophy)
- May exacerbate DM & hyperglycemia
- May impair ability to drive or operate machineries
- Special Instructions
- Take w/ food
- Use w/ caution in patients w/ sulfonamide allergy & hemophilia, liver disease
- Dosage Guidelines
- Treatment naive: 800 mg w/ Ritonavir 100 mg 24 hrly
- Treatment experienced: 600 mg 12 hrly w/ Ritonavir 100 mg 12 hrly
Fosamprenavir (FPV)
- Adverse Reactions
- GI effects (N/V); Dermatologic effects (rash, severe or life-threatening skin reactions have been reported); CNS effect (headache)
- Exacerbation of DM, hyperglycemia, immune reconstitution syndrome, fat redistribution have been reported
- Special Instructions
- May be taken w/ or w/o food
- Contraindicated in patients w/ previously demonstrated clinically significant hypersensitivity reactions (eg Stevens-Johnson syndrome) to any components of this product or to Amprenavir
- Discontinue in severe rash & for moderate rashes accompanied by systemic symptoms
- Concurrent administration of drugs that are highly dependent on CYP3A4 for clearance & for which elevated plasma levels are associated w/ serious or life-threatening events (eg Flecainide, Propafenone, Rifampin, ergot derivatives, Cisapride, St. John’s wort, Lovastatin, Simvastatin, Pimozide, Midazolam, Triazolam, Delavirdine) is contraindicated
- Use w/ caution in patients w/ known sulfonamide allergy, underlying hepatitis B or C or marked elevations in transaminases prior to treatment
- Dosage Guidelines
- ART-naive patients:
- Ritonavir-boosted Regimens:
- Once-daily regimen: Fosamprenavir 1400 mg PO 24 hrly + Ritonavir 100-200 mg PO 24 hrly
- Twice-daily regimen: Fosamprenavir 700 mg PO 12 hrly + Ritonavir 100 mg PO 12 hrly
Indinavir (IDV)
- Adverse Reactions
- GI effects (abdominal pain, N/V, diarrhea, regurgitation, dyspepsia, dry mouth); Metabolic effects (elevated liver enzymes, bilirubin, creatinine, phosphokinase, blood lipid levels); CNS effects (headache, dizziness, somnolence); Renal effects (nephrolithiasis, flank pain); Resp effects (cough, dyspnea); Other effects (alopecia, lipodystrophy, back pain)
- Potentially fatal acute hemolytic anemia & acute hepatitis have been reported
- Special Instructions
- Take on an empty stomach (best taken w/ plain water 1 hr before or 2 hr after meals)
- Contraindicated in severe hepatic impairment
- Use w/ caution in patients w/ increased risk of urolithiasis/nephrolithiasis, DM, hemophilia
- Ensure adequate hydration
- Monitor for signs of lipodystrophy
- Concurrent administration w/ Amiodarone, Cisapride, ergot derivatives, Lovastatin, Simvastatin, Alprazolam, Midazolam, Triazolam, Pimozide, Quinidine, Rifampin, Sildenafil, St John’s wort is contraindicated
- Dosage Guidelines
- 800 mg PO 8 hrly
- Combined w/ Efavirenz: 1000 mg PO 8 hrly
- Co-administered w/ Delavirdine, Itraconazole or Ketoconazole: 600 mg PO 8 hrly
- Combined w/ Lopinavir & Ritonavir: 600 mg PO 12 hrly
- Combined w/ Nelfinavir: 1200 mg PO 12 hrly
- Combined w/ Nevirapine: 1000 mg PO 8 hrly
- Combined w/ Rifabutin: 1000 mg PO 8 hrly (reduce Rifabutin to 1/2 the standard dose)
Nelfinavir (NFV)
- Adverse Reactions
- GI effects (diarrhea, nausea, flatulence); Endocrine & metabolic effects (hyperglycemia, dyslipidemia, lipodystrophy, hypertriglyceridemia, increased creatine kinase, elevated transaminases); Hematologic effects (decreased lymphocyte, neutrophil & hemoglobin counts)
- Special Instructions
- Take w/ food
- Concurrent administration w/ Amiodarone, Cisapride, ergot derivatives, Lovastatin, Simvastatin, Alprazolam, Midazolam, Triazolam, Pimozide, Quinidine, Rifampin, Sildenafil, St John’s wort is contraindicated
- Use w/ caution in hepatic & renal impairment, hemophilia A or B, DM
- Monitor for signs of lipodystrophy
- Dosage Guidelines
- 750 mg PO 8 hrly or
- 1250 mg PO 12 hrly
Ritonavir (RTV)
- Adverse Reactions
- CNS effects (asthenia, fatigue, headache, dizziness, seizures, anxiety, sweating, paresthesia); CV effects (syncope, orthostatic hypotension); GI effects (dry mouth, mouth ulcers, dyspepsia, N/V, diarrhea, taste disturbance, pancreatitis); Dermatologic effects (skin rashes, pruritus); Other effects (myalgia, renal insufficiency, anemia, elevated WBC count, raised prothrombin time, lipodystrophy, electrolyte imbalance)
- Potentially fatal hypersensitivity reactions, anaphylaxis, Stevens-Johnson syndrome have been reported
- Special Instructions
- Take w/ food
- Contraindicated in severe hepatic impairment
- Use w/ caution in DM, hemophilia, pancreatitis
- Discontinue treatment if patient develops hemolytic anemia
- Monitor levels of glucose, lipid, uric acid & blood count
- Ensure adequate hydration to reduce risk of nephrolithiasis
- Dosage Guidelines
- 600 mg PO 12 hrly
- Initial dose: No <300 mg PO 12 hrly x 3 days then increase dose by 100 mg PO 12 hrly at 2-3 day intervals up to the recommended dose of 600 mg PO 12 hrly over a period of not >14 days
- Dosing for PI-based regimens, please refer to dosages of other Protease Inhibitors
Saquinavir (SQV)
- Adverse Reactions
- GI effects (N/V, diarrhea, taste disturbances, abdominal pain, anorexia, flatulence); CNS effects (asthenia, fatigue, sleep disturbances, headache, dizziness, paresthesia, hypoesthesia); Musculoskeletal effects (myalgia, arthralgia, myositis, rhabdomyolysis); Endocrine & metabolic effects (hyperglycemia, onset or exacerbation of DM, irregular & prolonged heavy menstruation, sexual dysfunction); Other effects (lipodystrophy, blood disorders, ingrowing toenails & paronychia of the great toes, acute paranoid reactions)
- Potentially fatal hypersensitivity reactions, Stevens-Johnson syndrome, photosensitivity, nephrolithiasis, pancreatitis, hemorrhage, hemolytic anemia, intracranial hemorrhage, respiratory disorder have been reported
- Special Instructions
- Take w/ food (take at the same time as Ritonavir w/in 2 hr following a meal)
- Contraindicated in severe hepatic impairment
- Use w/ caution in renal & mild-moderate hepatic impairment, DM, hemophilia, underlying hepatitis B or other liver abnormalities
- Concomitant use w/ Sildenafil, NRTIs, Pimozide may cause serious arrhythmogenic, neurologic or other toxicities
- Dosage Guidelines
- Combined w/ Ritonavir: 1000 mg PO 12 hrly
Tipranavir (TPV)
- Adverse Reactions
- GI effects (diarrhea, N/V, abdominal pain); CNS effects (headache, fatigue); Metabolic effects (elevated transaminsases, total cholesterol & triglyceride levels); Other effects (fever, dehydration, wt loss, myalgia, rash, dyspnea; lipodystrophy)
- Special Instructions
- Should be taken w/ food
- Concurrent use of ergot derivatives, Cisapride, Pimozide, sedatives, Rifampicin, HMG Co-A inhibitors, immunosuppressive agents is contraindicated
- Use w/ caution in chronic hepatitis B or C coinfection, sulfonamide allergy, in those at increased risk of bleeding
- Contraindicated in patients w/ pretreatment liver enzyme levels >5x the upper limit of normal
- Monitor liver function, cholesterol & triglyceride levels before & during therapy
- Dosage Guidelines
- Combined w/ Ritonavir: 500 mg PO 12 hrly
1 Drug interactions listed above may not be comprehensive. Please see the latest MIMS for complete drug interaction & full prescribing information.
Boosted PI Regimens
- Ritonavir (RTV)-boosted PI-based regimens have demonstrated good immunologic & virologic responses
- Advantage: Drug resistance to most PIs require multiple mutations in the HIV protease gene & seldom develops after early virologic failure, esp when RTV boosting is used
- Disadvantage: Are often associated w/ more gastrointestinal (GI) symptoms than EFV-based regimens; like EFV-based regimens, are also associated w/ hepatic transaminase elevations
- Other disadvantages include higher pill burden & more clinically significant drug interactions are seen w/ RTV-boosted PI regimens than w/ NNRTI-based regimens
Atazanavir + Ritonavir (ATV/r)
- ATV/r & ATV/c combined w/ TDF/FTC are recommended as alternative regimens for ART-naive patients regardless of pre-treatment HIV RNA
- ATV/c + TDF/FTC is not recommended for patients w/ CrCl <70 mL/min
- ATV/r or ATV/c + ABC/3TC is recommended as other regimen
- Its use is limited to patients w/ pre-ART HIV RNA <100,000 copies/mL
- Advantage: A clinical trial has shown RTV-boosting of ATZ enhances ATV concentration, improving virologic activity as compared w/ ATV alone
- Disadvantage: Main adverse effect is indirect hyperbilirubinemia that is not associated w/ hepatic transaminase elevation; also requires acidic gastric pH for dissolution; thus, antacids, H2 agonists & proton pump inhibitors (PPI) may impair its absorption
Darunavir + Ritonavir (DRV/r)
- Regimen consisting of DRV/r + TDF/FTC is also a preferred PI-based regimen
- ARTEMIS study has shown DRV/r, compared w/ LPV/r (both in combination w/ TDF/FTC), to have a superior virologic response
Fosamprenavir + Ritonavir (FPV/r)
- Recommended as an alternative PI-based regimen, w/ once- or twice-daily dosing
- Studies have shown similar CD4 & virologic benefits when compared w/ ATV/r, both in combination w/ TDF/FTC
Indinavir + Ritonavir (IDV/r)
- Associated w/ high incidence of nephrolithiasis
- Indinavir requires high fluid intake
Lopinavir + Ritonavir (LPV/r)
- Is the only available coformulated boosted PI
- An alternative PI-based regimen for ART-naive patients
- Compared w/ other PIs boosted w/ 100 mg/daily of RTV, LPV/r should be boosted w/ 200 mg/day of RTV
- Associated w/ higher rates of GI side effects & hyperlipidemia
- Once-daily LPV/r should not be given to patients who have HIV mutations associated w/ PI resistance
- Twice-daily dosing is preferred for pregnant women, esp during 3rd trimester, when LPV levels are expected to decline
Lopinavir 100 mg/Ritonavir 25 mg tab; Lopinavir 200 mg/Ritonavir 50 mg tab; Lopinavir 400 mg/Ritonavir 100 mg (per 5 mL oral soln) 1
- Adverse Reactions
- GI effects (diarrhea, N/V, abdominal pain); CNS effect (headache); Metabolic effects (elevated liver enzyme, total cholesterol & triglyceride levels)
- Special Instructions
- Tab: May be taken w/ or w/o food
- Oral soln: Should be taken w/ food
- Once-daily administration is not recommended in therapy-experienced patients
- Concurrent use of ergot derivatives, Cisapride, Pimozide, sedatives, Rifampicin, HMG Co-A inhibitors is contraindicated
- Use w/ caution in pancreatitis, hepatic impairment, hemophilia
- See also Ritonavir Special Instructions
- Dosage Guidelines
- ART-naive: 400/100 mg PO 12 hrly (two 200/50 mg tab or 5 ml oral soln) or
- 800/200 mg PO 24 hrly (four 200/50 mg tab or 10 ml oral soln)
- ART-experienced, concomitant therapy w/ EFV, NVP: 6.5 ml (Lopinavir 533 mg/Ritonavir 133 mg) oral soln 12 hrly
Lopinavir + Ritonavir (LPV/r)
Saquinavir + Ritonavir (SQV/r)
- Has a high pill burden & requires twice-daily dosing & 200 mg of RTV
- At recommended dose, this regimen is associated w/ increases in both PR & QT prolongation
- Degree of QT prolongation is greater than that seen w/ some other boosted PI
- ECG is recommended prior to its initiation
- May be an acceptable regimen but should be used w/ caution against certain ART-naive patients (contraindicated in patients w/ QT prolongation, complete AV block, refractory hypokalemia or hypomagnesemia)
Unboosted PI-based Component
Atazanavir (ATV) 1
- Given once daily & has fewer effects on lipid profiles compared w/ other PIs
- May be an acceptable initial therapy when a once-daily regimen is desired & when there is concern for hyperlipidemia
- Studies have shown it to have similar virologic efficacy to ATV-based combination regimens w/ either EFV- or NVP-based regimens
- RTV boosting is needed when given w/ TDF or EFV since the latter can lower ATV concentration
- Adverse Reactions
- GI effects (N/V, diarrhea, taste disturbances, abdominal pain, anorexia, flatulence); CNS effects (asthenia, sleep disturbances, headache, dizziness, paresthesia, hypoesthesia); Musculoskeletal effects (myalgia, arthralgia, myositis, rhabdomyolysis); Dermatologic effects (alopecia, pruritus, rash which may be occasionally severe)
- Potentially fatal Stevens-Johnson syndrome & erythema multiforme have been reported
- Redistribution & accumulation of body fat may occur
- May prolong PR interval on ECG
- Special Instructions
- Take w/ food
- Concurrent administration w/ Cisapride, ergot derivatives, Rifampin, Irinotecan, Midazolam, Triazolam, Pimozide, Simvastatin, Lovastatin, Indinavir, PPIs, or St John’s wort is contraindicated
- Contraindicated in severe hepatic impairment
- Use w/ caution in patients w/ mild-moderate hepatic impairment, DM, hemophilia, history of cardiac conduction disorders
- Discontinue if acute hemolytic anemia occurs
- Monitor for signs of lipodystrophy
- Dosage Guidelines
- Treatment-naive: 400 mg PO 24 hrly or
- 300 mg PO 24 hrly (if combined w/ Ritonavir 100 mg)
- Treatment-experienced: Atazanavir 300 mg PO 24 hrly (combined w/ Ritonavir 100 mg)
1 Drug interactions listed above may not be comprehensive. Please see the latest MIMS for complete drug interaction & full prescribing information.
Top
Integrase Strand Transfer Inhibitor (INSTI)-based Regimen
Dolutegravir
- Inhibitor of HIV integrase
- Treatment of HIV-1 infection in adults & childn
- Licensed for both treatment-naive and treatment-experienced patients
- DTG/ABC/3TC is only given in patients who are HLA-B*5701 negative
- DTC plus TDF/FTC is now recommended for AR-naive patients
Elvitagravir
- Potent, CYP3A inhibitor that has no activity against HIV
-
EVG/c/TAF/FTC isNon-inferior to a combination of ATC + TDF/TC
-
EVG/c/TAF/FTC is only given in patients w/ pre-ART CrCl of >30 mL/min
-
EVG/c/TDF/FTC is only given in patients w/ pre-ART CrCl of >70 mL/min
Elvitagravir/Cobicistat (EVG/c)
Raltegravir (RAL)
- Approved for use in ART-naive patients
- Use has been associated w/ creatine kinase elevations; myositis & rhabdomyolysis have been reported
- A potential disadvantage when comparing w/ other regimens is its twice-daily dosing
- Like EFV, has a low genetic barrier to resistance
- The combination of Tenofovir/Emtricitabine & Raltegravir demonstrated similar virologic efficacy as that of EFV/TDF/FTC up to 156 weeks & is generally well tolerated
- Adverse Reactions
- GI effects (diarrhea, N/V); Resp effects (upper resp tract infection, nasopharyngitis, bronchitis); Other effects (headache, asthenia, pyrexia, fatigue)
- Special Instructions
- May be taken w/ or w/o food
- Use w/ caution in patients w/ history of myopathy or rhabdomyolysis
- Use w/ caution in patients w/ elevations in transaminases
- Rifampin may decrease the serum concentration of Raltegravir; increase dose of Raltegravir to 800 mg 12 hrly (adult dose) when used concomitantly w/ Rifampin
- Proton pump inhibitors may increase serum concentration of Raltegravir
- Dosage Guidelines
- 400 mg PO 12 hrly (in combination w/ other antiretroviral agents)
- Dosage adjustment for Rifampin co-administration: 800 mg PO 12 hrly
Raltegravir + 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- RAL + TDF/FTC is the preferred INSTI-based regimen for ART-naive patients, w/ immunologic & virologic responses similar to EFV + TDF/FTC & no safety concerns identified based on studies
- RAL + Abacavir (ABC)/Lamivudine (3TC) is the preferred alternative INSTI-based regimen
Nucleoside Reverse Transcriptase Inhibitors (NRTI)Triple NRTI Regimen 1,2
- Currently, three of the approved NRTIs have activity against hepatitis virus (HBV) --- 3TC, FTC & TDF
- Single- & dual-NRTI therapy are not recommended as these have not demonstrated sustained & potent virologic activity
- Stavudine (d4T) should not be used as 1st-line agent due to its metabolic toxicities
- Dual NRTIs are commonly used in combination w/ an NNRTI, a PI, an INSTI or a CCR5 antagonist
- In clinical practice, most dual NRTI combinations consist of a primary NRTI plus 3TC or FTC
- Lactic acidosis & severe hepatomegaly w/ steatosis, including fatal cases, have been reported w/ NRTIs alone or in combination
Abacavir (ABC)
- Adverse Reactions
- Dermatologic effects (rash, severe & potentially fatal hypersensitivity reactions may occur); GI effects (anorexia, N/V, diarrhea, abdominal pain); CNS effects (headache, fatigue, malaise, lethargy); Metabolic effects (elevated blood glucose & triglyceride levels); Other effects (fever, cough, dyspnea)
- May impair ability to drive or engage in tasks requiring alertness
- Special Instructions
- May be taken w/ or w/o food
- Contraindicated in moderate to severe renal & hepatic impairment, end-stage renal disease
- Use w/ caution in mild liver impairment; discontinue when liver function deteriorates or if hepatomegaly & unexplained metabolic acidosis develop
- Discontinue as soon as hypersensitivity is suspected
- Dosage Guidelines
- 300 mg PO 12 hrly or
- 600 mg PO 24 hrly
Didanosine (ddI)
- Adverse Reactions
- GI effects (pancreatitis, N/V, diarrhea, abdominal pain, hepatic failure); Dermatologic effect (rash); CNS effects (peripheral neuropathy, headache, fatigue); Metabolic effect (increased uric acid levels); Ocular effects (optic neuritis & retinal pigmentation)
- Patients may develop peripheral neuropathy, immune reconstitution syndrome & redistribution/accumulation of body fat
- Special Instructions
- Take on an empty stomach (1.5 hr before or 2 hr after meals)
- Use w/ caution in patients w/ history of pancreatitis & liver disease, in those w/ impaired hepatic & renal function, peripheral neuropathy, hyperuricemia
- Discontinue use in patients w/ confirmed pancreatitis
- Consider discontinuation or interruption in patients w/ worsening liver disease
- Patients may develop retinal changes & optic neuritis; half to yearly dilated retinal examinations are recommended
-
Dosage Guidelines
- Regular tab/cap or 10 mg/ml oral soln
- <60 kg: 125 mg PO 12 hrly or 250 mg PO 24 hrly
- ≥60 kg: 200 mg PO 12 hrly or 400 mg PO 24 hrly
- Twice-daily dosing is preferred
- Delayed-release cap:
- 25 kg to <60 kg: 250 mg PO 24 hrly
- ≥60 kg: 400 mg PO 24 hrly
-
With Tenofovir:
- ≥60 kg: 250 mg PO 24 hrly
- <60 kg: 200 mg PO 24 hrly
Emtricitabine (FTC)
- Adverse Reactions
- GI effects (diarrhea, N/V, dyspepsia, abdominal pain); Endocrine & metabolic effects (elevated amylase, lipase, creatine kinase, or LFT levels, hypertriglyceridemia, hypercholesterolemia, hyperglycemia, hyperlactatemia, insulin resistance, hyperbilirubinemia); CNS effects (headache, insomnia, dizziness, abnormal dreams, pain, asthenia); Other effects (anemia, neutropenia, rash, hyperpigmentation)
- Potentially fatal lactic acidosis & severe hepatomegaly w/ steatosis have been reported
- Special Instructions
- May be taken w/ or w/o food
- Use w/ caution in renal impairment, hepatomegaly, hepatic steatosis, hepatitis, hepatic impairment or those at risk for liver disease, in patients w/ hepatitis C coinfection, & patients on alpha-interferon & Ribavirin therapy
- Test for presence of chronic HBV infection prior to initiating therapy
- Discontinue use if there is a rapid rise in aminotransferase levels, progressive hepatomegaly or steatosis, metabolic or lactic acidosis of unknown cause
- Use w/ other Emtricitabine or Lamivudine-containing preparations is contraindicated
- Concurrent use of alpha-interferon increases risk of lactic acidosis
-
Dosage Guidelines
- 200 mg PO 24 hrly (as capsule) or
- 240 mg PO 24 hrly (as a 10 mg/ml soln)
Lamivudine (3TC)
- Adverse Reactions
- GI effects (abdominal pain, N/V, diarrhea); CNS effects (headache, peripheral neuropathy, insomnia); Metabolic effects (elevated creatine phosphokinase & alanine aminotransferase levels); Other effects (fever, cough, muscle pain, rash, alopecia, malaise, paronychia, angioedema, anaphylactoid reaction, urticaria)
- Potentially fatal lactic acidosis associated w/ severe hepatomegaly & hepatic steatosis have been reported
- Special Instructions
- May be taken w/ or w/o food
- Discontinue use if there is rapid rise in aminotransferase levels, progressive hepatomegaly, metabolic or lactic acidosis of unknown cause, if w/ clinical signs & symptoms or lab abnormalities suggestive of pancreatitis develop
- Use w/ caution in renal impairment, hepatomegaly or other risk factors for hepatic impairment
-
Dosage Guidelines
- 150 mg PO 12 hrly or
- 300 mg PO 24 hrly
Stavudine (d4T)
- Adverse Reactions
- GI effects (N/V, abdominal pain, anorexia); CNS effects (headache, asthenia, insomnia, mood changes); Dermatologic effects (skin rashes, pruritus); Hematologic effects (neutropenia, thrombocytopenia); Other effects (arthralgia, myalgia, influenza-like syndrome, dyspnea, pharyngitis)
- Special Instructions
- May be taken w/ or w/o food
- Use w/ caution in patients w/ hepatomegaly or other risk factors for liver disease, w/ history of peripheral neuropathy, in renal impairment
- Discontinue use if peripheral neuropathy develops, if there is rapid rise in aminotransferase levels, progressive hepatomegaly, metabolic or lactic acidosis of unknown cause
- Monitor for signs of pancreatitis; avoid concurrent administration of drugs that cause pancreatitis (eg IV Pentamidine), peripheral neuropathy (eg Metronidazole, Isoniazid, Vincristine)
- Risk of adverse effects (eg hepatotoxicity, peripheral neuropathy, pancreatitis) is increased if used w/ Didanosine & Hydroxycarbamide
-
Dosage Guidelines
- <60 kg: 30 mg PO 12 hrly
- ≥60 kg: 40 mg PO 12 hrly
Tenofovir (TDF)
- Adverse Reactions
- GI effects (N/V, diarrhea, abdominal pain, flatulence, anorexia, dyspepsia, hepatitis); Metabolic effects (hypophosphatemia, increased amylase & liver enzymes, hypertriglyceridemia, hyperglycemia); CNS effects (peripheral neuropathy, headache, depression, asthenia, dizziness, insomnia); Renal effects (nephritis, nephrogenic diabetes insipidus, renal impairment, Fanconic syndrome); Other effects (body fat redistribution, osteomalacia, immune reconstitution syndrome)
- Special Instructions
- May be taken w/ or w/o food
- Use w/ caution in renal impairment, hepatomegaly or in those at risk for liver disease
- Discontinue use if there is rapid rise in aminotransferase levels, progressive hepatomegaly or steatosis, metabolic or lactic acidosis of unknown cause
- Monitor creatinine clearance & serum phosphorus routinely in patients at risk of renal impairment
- Bone monitoring for patients w/ history of pathologic bone fracture or those at risk of osteopenia
Zalcitabine (ddC)
- Adverse Reactions
- CNS effects (numbness, sharp shooting pain, asthenia, fatigue, mood changes); CV effects (cardiomyopathy, heart failure, chest pain); GI effects (oral & esophageal ulceration, constipation, diarrhea); Dermatologic effects (rash, alopecia, pruritus); Metabolic effects (elevated LFTs, hyperuricemia); Other effects (hypersensitivity reactions, hematologic effects, arthralgia, myalgia, dyspnea, pharyngitis, hearing, visual & renal disturbances)
- Potentially fatal hepatic failure, pancreatitis, lactic acidosis & severe hepatomegaly w/ steatosis have been reported
- Special Instructions
- Should be taken on an empty stomach (at least 1 hr before or 2 hr after meals)
- Contraindicated in those w/ or at risk of peripheral neuropathy
- Use w/ caution in patients w/ history of pancreatitis or increased serum amylase; in cardiomyopathy, heart failure, renal or hepatic impairment
- Discontinue if pancreatitis, lactic acidosis, hepatic dysfunction, or peripheral neuropathy develops
- Perform baseline serum amylase & triglycerides in patients w/ previous history of pancreatitis, elevated amylase, or alcohol abuse
Zidovudine (ZDV)
- Adverse Reactions
- GI effects (N/V, anorexia, diarrhea, taste perversion, elevated LFT, pancreatitis); CNS effects (severe headache, insomnia, asthenia, convulsions); Dermatologic effects (nail, skin & oral mucosa pigmentation); Other effects (myalgia, myopathy, fat redistribution)
- Potentially fatal hepatotoxicity, lactic acidosis & severe hepatomegaly w/ steatosis, blood dyscrasias (eg serious anemia that may require transfusion, neutropenia, leukopenia) have been reported
- Special Instructions
- May be taken w/ or w/o food
- Use w/ caution in patients w/ renal & hepatic impairment, anemia or myelosuppression
- Monitor patients w/ risk factors for liver disease
- Blood tests should be carried out regularly; decrease dose if neutrophil or hemoglobin count is low
- Monitor serum creatine kinase every 3 months in patients who have received >6 months of treatment
-
Dosage Guidelines
- 300 mg PO 12 hrly or
- 200 mg PO 8 hrly
1 Combinations of NNRTIs & NRTIs are available. Specific prescribing information may be found in the latest MIMS.
2 Drug interactions listed above may not be comprehensive. Please see the latest MIMS for complete drug interaction & full prescribing information.
Top
Preferred Dual NRTI
Tenofovir (TDF)/Emtricitabine (FTC) [coformulated]
- Tenofovir is a nucleotide analog w/ potent activity against both HIV & hepatitis B virus (HBV)
- Has a long intracellular half-life which allows for once-daily dosing
- Demonstrated potent virologic activity when used w/ either 3TC or FTC as part of an EFV-based regimen in ART-naive patients
- Renal impairment w/ TDF use has been reported; greater risk of renal dysfunction when used in PI-based regimens
- TDF plus either 3TC or FTC is the preferred NRTI combination, esp for patients coinfected w/ both HIV & HBV
- Use of a single HBV-active NRTI (either 3TC or FTC) is not recommended as it can lead to HBV resistance
- Superior to ZDV/3TC in virologic efficacy up to 144 weeks
Emtricitabine 200 mg/ Tenofovir 300 mg
- Adverse Reactions
- See individual components
- Special Instructions
- May be administered w/ or w/o food
- See individual components
Alternative Dual NRTI
Abacavir (ABC)/Lamivudine (3TC) [coformulated]
- Remains a good alternative dual-NRTI option for some ART-naive patients
- Should only be given to patients who tested negative for HLA-B*5701
- Abacavir has the potential for serious hypersensitivity reactions
- The fixed dose combination allows for once-daily dosing
- Should be used w/ caution in patients at higher risk for cardiovascular disease & whose plasma HIV RNA levels are at ≥100,000 copies/mL
Abacavir 600 mg/ Lamivudine 300 mg
- Adverse Reactions
- See individual components
- Special Instructions
- May be administered w/ or w/o food
- See individual components
- Dosage Guidelines
-
1 tab PO 24 hrly
Acceptable Dual NRTI
Zidovudine (ZDV)/Lamivudine (3TC) [coformulated]
Lamivudine 150 mg/ Zidovudine 300 mg
- Adverse Reactions
- See individual components
- Special Instructions
- May be administered w/ or w/o food
- See individual components
- Dosage Guidelines
Triple NRTI
- Triple NRTI regimens have been shown to have suboptimal virologic activity based on several controlled trials
ABC/3TC/ZDV (coformulated)
- The only triple NRTI combination w/ available supporting randomized clinical trial data
- With comparable virologic activity to IDV- & NFV-based regimens but was inferior to EFV-based regimen
- Generally not recommended & should only be used when a preferred alternative or an acceptable NNRTI-, PI-, or INSTI-based regimen is less desirable due to toxicities, complexity of regimen or drug interactio
Abacavir 300 mg/ Lamivudine 150 mg/ Zidovudine 300 mg
- Adverse Reactions
- See individual components
- Special Instructions
- May be administered w/ or w/o food
- See individual components
- Dosage Guidelines
CCR5 Antagonist-based Regimens
CCR5-Antagonist (eg Maraviroc) + 2 NRTIs (Zidovudine/Lamivudine)
- Maraviroc (MVC) is recommended only as an acceptable regimen for ART-naive patients due to its limited experience w/ regimens other than ZDV/3TC, its cost (requires tropism assay prior to use), & requirement for twice-daily dosing
Other Antiretroviral Regimens for Initial Therapy when Abacavir or Tenofovir Cannot be Used
Darunavir/Ritonavir + Raltegravir (DRV/r + RAL)
- Considered in patients w/ HIV RNA <100,000 copies/uL, CD4 cell counts >200/mm3 & those who cannot take either TDF or ABC
Lopinavir/Ritonavir + Lamivudine (LPV/r + 3TC)
- Recommended as initial therapy when both TDF & ABC are contraindicated
Recommended Antiretroviral Drug Regimens for Antiretroviral Naive Patients
Preferred PI-based Regimens |
Ritonavir-boosted Darunavir + Tenofovir disoproxil fumarate/Emtricitabine1
|
Preferred INSTI-based Regimens |
Dolutegravir/Abacavir/Lamivudine1
Dolutegravir + Tenofovir disoproxil fumarate/Emtricitabine1
Cobicistat-boosted Elvitegravir/Tenofovir alafenamide fumarate/Emtricitabine
Cobicistat-boosted Elvitegravir/Tenofovir disoproxil fumarate/Emtricitabine
Raltegravir + Tenofovir disoproxil fumarate/Emtricitabine1
|
Alternative NNRTI-based Regimens |
Efavirenz/Tenofovir disoproxil fumarate/Emtricitabine1
Rilpivirine/Tenofovir disoproxil fumarate/Emtricitabine1
|
Alternative PI-based Regimens |
Cobicistat-boosted Atazanavir + Tenofovir disoproxil fumarate/Emtricitabine1
Ritonavir-boosted Atazanavir + Tenofovir disoproxil fumarate/Emtricitabine1
(Cobicistat-boosted Darunavir or Ritonavir-boosted Darunavir) + Abacavir/Lamivudine1
Cobicistat-boosted Darunavir + Tenofovir disoproxil fumarate/Emtricitabine1
|
Other INSTI-based Regimens |
Raltegravir + Abacavir/Lamivudine1
|
Other NNRTI-based Regimens |
Efavirenz + Abacavir/Lamivudine1
|
Other PI-based Regimens |
(Cobicistat-boosted Atazanavir or Ritonavir-boosted Atazanavir) + Abacavir/Lamivudine
Ritonavir-boosted Lopinavir (once2 or twice daily) + Abacavir/Lamivudine1
Ritonavir-boosted Lopinavir (once2 or twice daily) + Tenofovir disoproxil fumarate/Lamivudine1
|
Other Regimens When TDF or ABC Cannot be Used |
Ritonavir-boosted Duranavir + Raltegravir
Ritonavir-boosted Lopinavir (twice daily) + Lamivudine (twice daily)
|
Adapted from: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2016.
1 3TC may be substituted for FTC & vice-versa
2 Once daily LPV/r is not recommended in pregnant patients
Efavirenz 600 mg/ Emtricitabine 200 mg/Tenofovir 300 mg
- Adverse Reactions
- See individual components
- Special Instructions
- Should be taken on an empty stomach (dosing at bedtime to improve tolerability of nervous system symptoms)
- See individual components
- Dosage Guidelines
Rilpivirine 25 mg/Emtricitabine 200 mg/Tenofovir 300 mg
- Adverse Reactions
- See individual components
- Special Instructions
- Administer w/ meals (preferably high fat)
- See individual components
- Dosage Guidelines
Top
Other Antivirals 1
Enfuvirtide (T20)
- Adverse Reactions
- GI effects (diarrhea, nausea, abdominal pain); CNS effects (fatigue, insomnia); Local effects (pain, infection, erythema at site of inj)
- Special Instructions
- Local inj site reactions are common. Administration using a needle-free device has been associated w/ nerve pain, bruising, & hematomas at sites when large nerves are close to the skin; administer only in recommended sites
- Use w/ caution in patients w/ coagulation disorders or in those receiving anticoagulants due to increased risk of bleeding at inj site
- Dosage Guidelines
- Adults & Childn >16 yr: 90 mg SC 12 hrly
Maraviroc (MVC)
- Adverse Reactions
- GI effects (GI disorders, dysgeusia); CNS effects (dizziness, asthenia, somnolence, paresthesia, insomnia); Other effects (increased transaminases, rash, pruritus, back pain, muscle spasms)
- Special Instructions
- May be taken w/ or w/o food
- Use w/ caution in patients w/ renal or hepatic impairment, patients at risk for CV events, history of postural hypotension
- Dosage Guidelines
- 150 mg PO 12 hrly or
- 300 mg PO 12 hrly or
- 600 mg PO 12 hrly
1 Drug interactions listed above may not be comprehensive. Please see the latest MIMS for complete drug interaction & full prescribing information.
Top
Management of Patients w/ Treatment Failure
Consider expert referral for all patients who experience treatment failure
General Approach to Patients w/ Virologic Failure
- Evaluation should include assessment of adherence, drug-drug or drug-food interaction, drug tolerability & severity of the patient’s HIV disease, history of ART, concomitant medications, results of prior drug resistance testing, & CD4 & HIV RNA counts over time
- Identify possible clinical scenario involved in treatment failure (eg patient adherence, timing of the drug resistance test, presence of a highly drug resistant HIV)
- Goal of treatment in ART-experienced patients w/ drug resistance who are experiencing failure is to re-establish virologic suppression (<48 copies/mL)
- Change the ART regimen as soon as virologic failure is confirmed
- There is no consensus for the optimal time to change therapy
- Patients who failed 2nd-line agents w/o new antiretroviral options should continue w/ a tolerated regimen
- The goal is to suppress HIV replication to a level where drug resistance mutations do not emerge
- To establish a new ART regimen, review patient’s treatment history, including results of both past & current resistance tests, & identify at least 2 (preferably 3) fully active agents to combine w/ an optimized background ART regimen
- Fully active agents are those that are likely to have virologic activity based on the patient’s drug resistance test results, treatment history & the drug’s mechanism of action
- Adding a single fully active agent is not recommended since this increases the risk of rapid development of resistance
- But in patients w/ a high chance of clinical progression & limited drug options, adding a single drug regimen may reduce risk of immediate clinical progression
- Interrupting or discontinuing treatment is not recommended since this may lead to rapid decline in the CD4 count & rise in HIV RNA & may increase the risk for clinical progression
- In cases of patients that are highly ART experienced, where maximal virologic response is not possible, ART should be continued w/ regimens that are designed to preserve CD4 cell counts, avoid clinical progression, & minimize toxicity
- In patients with limited drug choices & a high likelihood of clinical progression (eg CD4 count <100 cells/mm3), adding a single ART agent may reduce the risk of immediate clinical progression
- May produce transient increases in CD4 cell counts &/or decreases in HIV RNA which have been associated w/ clinical benefits
Management of Immunologic Failure
- Focus on patients w/ CD4 counts <200 cells/mm3
- Currently, it is not clear if immunologic failure in the setting of virologic suppression should prompt a change in the ART regimen; various strategies are still under investigation
- Immune-based therapies should not be used except for clinical trials
All dosage recommendations are for non-pregnant & non-breastfeeding women, non-elderly adults w/ normal renal & hepatic function unless otherwise stated.
Not all products are available or approved for above use in all countries.
Products listed above may not be mentioned in the disease management chart but have been placed here based on indications listed in regional manufacturers’ product information.
Click the link below for specific prescribing information of products available in respective countries.
Brands available in:
Hong Kong
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Top